Frequency Therapeutics doses first patient in FX-345 study

Frequency Therapeutics announced that it has dosed a first patient in the Phase 1b study of FX-345, the company’s second hearing restoration candidate for sensorineural hearing loss, or SNHL. FX-345 is a combination of two small molecules and, similar to Frequency’s lead hearing candidate FX-322, is designed to restore inner ear cells needed for hearing. However, FX-345 includes a more potent GSK3 inhibitor, a new chemical entity that may enable targeted drug exposure further into the cochlea. Future clinical studies will determine whether greater cochlear drug exposure can address additional populations of individuals with SNHL.